Tarsus Pharmaceuticals — Third Quarter 2026 Earnings Summary

Tarsus Pharmaceuticals reported third-quarter 2026 net product sales of $194.6 million for XDEMVY, representing a 64% year-over-year increase and surpassing $1 billion in cumulative sales since launch. The company dispensed over one million bottles of the Demodex blepharitis treatment during the quarter while appointing Neera Clase as its new Chief Commercial Officer. Financial results for the period included a net loss of $668.3 million, driven largely by $632.2 million in acquired in-process research and development expenses from the iRenix and Alkeus acquisitions. The firm continues to advance its pipeline with upcoming clinical milestones for TP-04, TP-05, IRX-101, and gildeuretinol expected between 2027 and 2029.